Compounds > lestaurtinib
Page last updated: 2024-09-03

lestaurtinib and ponatinib

lestaurtinib has been researched along with ponatinib in 5 studies

Compound Research Comparison

Studies
(lestaurtinib)		Trials
(lestaurtinib)		Recent Studies (post-2010)
(lestaurtinib)		Studies
(ponatinib)		Trials
(ponatinib)		Recent Studies (post-2010) (ponatinib)
124126353834519

Protein Interaction Comparison

ProteinTaxonomylestaurtinib (IC50)ponatinib (IC50)
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)0.0038
Tyrosine-protein kinase JAK2Homo sapiens (human)0.169
Tyrosine-protein kinase ABL1Homo sapiens (human)0.0037
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.0009
High affinity nerve growth factor receptorHomo sapiens (human)0.0114
Tyrosine-protein kinase LckHomo sapiens (human)0.0003
Tyrosine-protein kinase FynHomo sapiens (human)0.0004
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0086
Tyrosine-protein kinase YesHomo sapiens (human)0.0009
Tyrosine-protein kinase LynHomo sapiens (human)0.0008
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.0357
Hepatocyte growth factor receptorHomo sapiens (human)0.0017
Tyrosine-protein kinase HCKHomo sapiens (human)0.0001
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0012
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0271
Breakpoint cluster region proteinHomo sapiens (human)0.0008
Fibroblast growth factor receptor 1Homo sapiens (human)0.0016
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0053
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0016
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)0.613
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0123
Ephrin type-A receptor 1Homo sapiens (human)0.143
Fibroblast growth factor receptor 2Homo sapiens (human)0.0018
Fibroblast growth factor receptor 4Homo sapiens (human)0.0058
Fibroblast growth factor receptor 3Homo sapiens (human)0.0099
Tyrosine-protein kinase JAK1Homo sapiens (human)0.0322
Ephrin type-A receptor 2Homo sapiens (human)0.0013
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0053
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0086
Tyrosine-protein kinase CSKHomo sapiens (human)0.0127
Tyrosine-protein kinase FRKHomo sapiens (human)0.0013
Glycogen synthase kinase-3 betaHomo sapiens (human)2.8
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0094
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)4.385
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.012
Coiled-coil domain-containing protein 6Homo sapiens (human)0.1804
Mitogen-activated protein kinase 14Homo sapiens (human)0.01
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)0.48
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.04
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)0.0016

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S1
Fancher, KM; Green, MR; Newton, MD1
Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM1
Kangussu-Marcolino, MM; Singh, U1

Reviews

2 review(s) available for lestaurtinib and ponatinib

ArticleYear
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant

2016
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Minerva medica, 2020, Volume: 111, Issue:5

    Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine

2020

Other Studies

3 other study(ies) available for lestaurtinib and ponatinib

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Bioorganic & medicinal chemistry, 2022, 02-15, Volume: 56

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship

2022
Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica.
    Antimicrobial agents and chemotherapy, 2022, 02-15, Volume: 66, Issue:2

    Topics: Animals; Carbazoles; Drug Repositioning; Entamoeba histolytica; Female; Furans; Humans; Imidazoles; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Pregnancy; Pyridazines; TOR Serine-Threonine Kinases

2022